Viemed Healthcare AI Stock Analysis
Viemed Healthcare (VIJ) AI Stock Analysis
Viemed Healthcare
(Frankfurt:VIJ)
No summary available
Viemed Healthcare (VIJ) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 343.69M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- 22.3
- Beta (1Y)
- 0.28
- Revenue Growth
- 16.05%
- EPS Growth
- 11.93%
- Country
- Germany
- Employees
- 1,490
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
Viemed Healthcare Business Overview & Revenue Model
Company Description
Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The company provides respiratory disease management solutions, including treatment of chroni...
Viemed Healthcare Earnings Call Summary
The call was broadly positive, led by record revenue, double-digit organic growth, strong net income and adjusted EBITDA expansion, growing sleep and maternal health volumes, improving ventilation revenue, capital returns, and higher revenue guidance. The primary challenges were slightly lower gross margin, increased audit-related work and payment timing, temporarily weaker cash conversion, volatility in ventilation active patients, and a lower upper end to adjusted EBITDA guidance.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management now expects full-year revenue of $316 million to $320 million, compared with the previous range of $314 million to $320 million; adjusted EBITDA guidance is $64 million to $66 million, compared with the previous range of $64 million to $68 million; and net CapEx is expected to be 8% to 9% of revenue, compared with 8.5% to 10% previously. The revised outlook anticipates sequential growth in both revenue and adjusted EBITDA in the fourth quarter and excludes any potential future acquisitions or strategic transactions. Viemed is on track to enter 2 additional states per quarter beginning in the fourth quarter for maternal health, expects ventilator active patient count to be back up in the fourth quarter, and expects to stay up in the 20-plus percent adjusted EBITDA for the time being.
Viemed Healthcare Risk Analysis
Viemed Healthcare disclosed 39 risk factors in its most recent earnings report. Viemed Healthcare reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksViemed Healthcare Peers Comparison
Overall Rating
ADUS83Outperform
EHC70Outperform
NHC68Neutral
AVAH65Neutral
PNTG61Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 83Outperform | $2.27B | 20.38 | 9.81% | ― | 11.53% | 27.72% | |
| 70Outperform | $13.53B | 21.46 | 25.17% | 0.57% | 9.36% | 20.78% | |
| 68Neutral | $3.22B | 27.85 | 10.41% | 1.27% | 5.71% | 12.44% | |
| 65Neutral | $2.54B | 7.94 | 115.53% | ― | 16.84% | 280.13% | |
| 61Neutral | $1.28B | 35.36 | 10.15% | ― | 38.67% | 33.07% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:VIJ | Viemed Healthcare US | 7.95 | 2.80 | 54.37% | |
| ADUS | Addus HomeCare Corporation | 121.56 | 11.49 | 10.44% | |
| EHC | Encompass Health | 137.88 | 25.92 | 23.15% | |
| NHC | National Healthcare | 205.77 | 80.29 | 63.98% | |
| PNTG | Pennant Group Inc | 36.50 | 10.59 | 40.87% | |
| AVAH | Aveanna Healthcare Holdings Inc | 11.65 | 3.35 | 40.36% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
